medigraphic.com
Colegio de Medicina Interna de México.

2011, Number 4

<< Back Next >>

Med Int Mex 2011; 27 (4)

The population pharmacokinetics and its relevance in therapeutics

Barranco GLM, Neri SJC, León MH, Carrasco PMC, Flores MFJ, Patiño CSI

Language: Spanish
References: 43
Page: 370-377
PDF size: 431.50 Kb.


ABSTRACT

Population pharmacokinetics has its main application in the study of the behavior of drugs, by estimating the average values of pharmacokinetic parameters in a group of individuals or a population of patients and the inter-individual variability associated with these parameters. The variability of drug response depends on various characteristics related to the pathophysiological situation of patients such as age, gender, weight, genetic factors, environmental factors, diseases, health status, etc. Population models provide an initial guide to develop dosing regimens to achieve and maintain a certain plasma concentration in each patient. The purpose of this review article is to understand the applications of population pharmacokinetic studies and identify the intrinsic and extrinsic characteristics that may influence the pharmacokinetics of the drugs tested.


REFERENCES

  1. Aarons L. Population pharmacokinetics: theory and practice. Br J Clin Pharmacol 1991;32:669–670.

  2. Herrera J, Manual de Farmacia Clínica y Atención Farmacéutica. 1ª edición. Madrid: Elsevier, 2003.

  3. Ramesh N, Socorrina Colaco, Koumaravel K, Kumar EP. Population Pharmacokinetics. Review article. IJPBS 2010; 1(3):1-6.

  4. Ette EI, Williams PJ. Population pharmacokinetics I: background, concepts, and models. Ann Pharmacother 2004;38:1702-1706.

  5. Ette EI, Williams PJ, Lane JR. Population Pharmacokinetics III: Design, Analysis, and Application of Population Pharmacokinetic Studies. Ann Pharmacother 2004;38:2136-2144.

  6. Dodge WF, Jelliffe RW, Richardson CJ, Bellanger RA, Hokanson JA y cols. Population pharmacokinetic models: measures of central tendency. Drug Investigation 1993:5:206-211.

  7. Fattinger KE, Sheiner LB, and Verotta D. A New Method to Explore the Distribution of Interindividual Random Effects in Non-Linear Mixed Effects Models. Biometrics 1996;51:1236-1251.

  8. FDA, Food and Drug Administration. Population Pharmacokinetics, Guidance for Industry. U.S. Department of Health and Human Services. Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), February 1999. http://www.fda.gov/cder/guidance/1852fnl.pdf

  9. William P J, Ette E I. The Role of Population Pharmacokinetics in Drug Development in Light of the Food and Drug Administration’s ‘Guidance for Industry: Population Phamracokinetics’. Clin Pharmacokinet 2000;39:385-395.

  10. Karlsson MO, Thomson AH, McGovern EM, Chow P, Evan TJ, Kelman AW. Population pharmacokinetics of rectal theophylline in neonates. Ther Drug Monit 1991;13:1995-2000.

  11. Romano S, Fernández de Gatta MM, Calvo V, Méndez E, Dominguez- Gil A, Lanao JM. Population pharmacokinetics of amikacin in patients with haematological malignancies. J Antimic Chemother 1999; 44:235-242.

  12. Serrano BB, García-Sánchez MJ, Otero MJ, Buelga DS, Serrano J, Domínguez-Gil A. Valproate population pharmacokinetics in children. J Clin Pharm Ther 1999;24:73-80.

  13. Samara E, Granne R. Role of Pharmacokinetics in Drug Development: a Pharmaceutical Industry Perspective. Clin Pharmacokinet 1997;32:294-312.

  14. Whiting B, Kelman AW, Grevel J. Population Pharmacokinetics: Theory and Clinical Application. Clin Pharmacokinet 1986;11:387-401.

  15. Schwartz JB. The Influence of Sex on Pharmacokinetics. Clinical Pharmacokinetic 2003;42:107-121.

  16. Carrasco-Portugal MC, Flores-Murrieta FJ. Gender differences in the pharmacokinetic of fluconazole. Clin Drug Invest 2007;27:851-855.

  17. Flores Perez J, Juarez Olguin H, Flores Perez C, Perez Guille G, et al. Effects of gender and phase of the menstrual cycle on the kinetics of ranitidine in healthy volunteers. Chronobiol Int 2003; 20:485-494.

  18. Seeman MV. Gender Differences in the Prescribing of Antipsychotic Drugs. Am J Psychiatry 2004;161:1324-1333.

  19. Schwartz JB. The Current State of Knowledge on Age, Sex, and Their Interactions on Clinical. Pharmacology 2007;82:87-96.

  20. Wilkinson GR. Drug Metabolism and Variability among Patients in Drug Response. N Engl J Med 2005;352:2211-2221.

  21. Gainsborough N, Maskrey VL, Nelson ML, et al. The association of age with gastric emptying. Age Ageing1993;22:37- 40.

  22. Shi S, Mörike K, KlotzU. The clinical implications of ageing for rational drug therapy. Eur J Clin Pharmacol 2008;64:183-199.

  23. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010;49:71-87.

  24. Poggesi I, Benedetti MS, Whomsley R, Le Lamer S, et al. Pharmacokinetics in special populations. Drug Metab Rev 2009;41:422-454.

  25. Allegaert K, van den Anker JN, Naulaers G, de Hoon J. Determinants of drug metabolism in early neonatal life. Curr Clin Pharmacol 2007;2:23-29.

  26. Bartelink IH, Rademaker CM, Schobben AF, van den Anker JN. Guidelines on pediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet 2006;45:1077-1097.

  27. Hilmer SN, McLachlan AJ, Le Couteur DG. Clinical pharmacology in the geriatric patient. Fundam Clin Pharmacol 2007;21:217-230.

  28. Heft MW, Mariotti AJ. Geriatric pharmacology. Dent Clin North Am 2002;46:869-885.

  29. Brunton L, Lazo J, Keith L, et al. Goodman and Gilman's The Pharmacologic Basis of Therapeutics, 11th ed. New York: McGraw-Hill, 2006.

  30. Dot D, Miró J, Fuentes-Arderiu X. Within-Subject and betweensubject biological variation of prothrombin time and activated partial thromboplastin time. Ann Clin Biochem 1992;29:422-425.

  31. Keifer J,. Glass P. Contex-sensitive half -time and anesthesia: how does theory match reality? Curr Opin Anaestesiol 1999;12:43-48.

  32. Reidenberg MM. The discipline of clinical pharmacology. Clin Pharmacol Ther 1985;38:2-5.

  33. Sheiner LB, Grasela TH. An introduction to mixed effect modeling: concepts, definitions and justification. J Pharmacokinet Biopharm 1991;19:11S-24S.

  34. Sun H, Fadiran EO, Jones CD, Lesko L, et al. Population pharmacokinetics. A regulatory perspective. Clin Pharmacokinet 1999;37:41-58.

  35. Vozeh S, Steimer JL, Rowland M, et al., The Use of Population Pharmacokinetics in Drug Development. Clin Pharmacokinet 1996;30:81- 93.

  36. Martínez LJ. II Curso de Farmacocinética Clínica y Poblacional. Instituto Nacional de Neurología y Neurocirugía. México, DF 2003.

  37. Mangues MA, Troconiz IF, Soy D, Moreira SR, y col. Análisis farmacocinético poblacional de gentamicina en neonatos. Farmacia Hospitalaria 2001;25:284-292.

  38. Grasela TH, Sheiner LB. Pharmacostatistical modelling for observational data. J Pharmacokin Biopharm 1991;19:25S-36S.

  39. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm 1992; 20:511-528.

  40. Jonsson EN, Karlsson MO. Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58:51-64.

  41. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr 1974;19:716-723.

  42. Calvo MV, García MJ, Martínez J, Fernández MM. Farmacocinética Clínica http://sefh.interguias.com/libros/tomo1/Tomo1_Cap2-12.pdf.

  43. Smith MK. 2004. Software for non-linear mixed effects modeling. RSS meeting, London 2004.




2020     |     www.medigraphic.com